FDA Approved: PROLIA — Supplemental Application (Amgen, Inc)

View source ↗

Summary

The FDA approved a supplemental application for PROLIA (denosumab) submitted by Amgen, Inc., signaling an approved modification to its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Osteoporosis

Drugs mentioned

• Prolia (denosumab)

Snippet

SUPPL AP for PROLIA (DENOSUMAB)